Form 4: NeoGenomics Director Equity Transaction Update

Director Lynn Tetrault acquired 23,077 shares of NeoGenomics common stock through the vesting of restricted stock units.

Summary

• Director Lynn Tetrault acquired 23,077 shares of common stock on June 1, 2026, via the vesting of restricted stock units (RSUs).
• The reporting person was granted 11,069 stock options with an exercise price of $10.52 and 15,970 new RSUs on the same date.
• Following these transactions, the director holds 96,729 shares directly and 7,000 shares indirectly through a rollover IRA.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it reflects standard director compensation rather than a strategic shift or market-moving financial performance.

Positives

• Director maintains a significant long-term equity stake in the company.
• Continued alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified; this is a standard compensatory equity transaction.

Risks

• Market volatility affecting the value of equity-based compensation.
• Potential dilution from the issuance of new stock options and RSUs.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity transactions.

Management Comments

• No narrative comments provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that this filing represents routine director compensation and equity alignment, which is standard practice for publicly traded biotechnology and diagnostic companies to ensure board members remain incentivized toward long-term growth.

Comparison to Industry Standards

• The use of RSU vesting and stock option grants for board compensation is consistent with standard corporate governance practices in the healthcare diagnostics sector.
• The transaction volume is typical for a director of a company with NeoGenomics' market capitalization.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensatory grants.

Next Steps

• Future vesting of the newly granted 15,970 RSUs.
• Potential future exercise of stock options granted.

Key Dates

Keywords

NeoGenomics, NEO, Form 4, Insider Trading, Equity Compensation, Director Ownership